Eli Lilly’s $3.8 Billion Psychedelic Bet Puts Atai Beckley in a Holding Pattern
Published on 07/20/2026 at 17:06 | Redaktion boerse-global.de
The pharmaceutical industry’s appetite for psychedelic therapies has reached a new intensity. In the latest and largest bet yet, Eli Lilly is paying up to $3.8 billion to acquire Atai Beckley, the transatlantic developer formed in November 2025 from the merger of atai Life Sciences and Beckley Psytech. The deal, announced on July 16, catapulted the stock to a 52-week high of €7.85 that same day, but the subsequent trading has been a study in capped enthusiasm.
Lilly’s offer structure is straightforward: $6.75 per share in cash — roughly $2.8 billion fixed — plus a contingent value right of up to $2.50 per share that could add another $1 billion if specific milestones are met. Those milestones include the Phase?3 initiation of VLS-01 within four years, U.S. approval of BPL-003 within five years, and U.S. approval of VLS-01 within seven years. The transaction is expected to close in the third quarter of 2026.
At the heart of the acquisition is BPL-003, an intranasal 5?MeO?DMT formulation for treatment-resistant depression that has already secured FDA Breakthrough Therapy designation after a successful Phase?2b study. In earlier Phase?2a data, a single 10?mg dose produced symptom improvement that persisted at 12?weeks in 83?% of patients. Competition in this space is intensifying: AbbVie paid up to $1.2?billion for Gilgamesh and its compound Bretisilocin, while Otsuka acquired Transcend for $700?million. Meanwhile, Compass Pathways is advancing its own psilocybin candidate, COMP360, through Phase?3.
Pipeline assets beyond BPL-003 include VLS-01, a DMT buccal film now in Phase?2b, and EMP-01, an R?MDMA candidate targeting social anxiety disorder that is in Phase?2a. Jefferies analyst Andrew Tsai sees a commercial opportunity of $1?billion to $2?billion for BPL?003 if Phase?3 reads out positively — results are expected around early 2029. Canaccord Genuity is even more bullish, projecting U.S. sales of BPL?003 reaching $3.7?billion by 2036, assuming an annual treatment cost of roughly $30,000 per patient.
Should investors sell immediately? Or is it worth buying Atai Beckley?
The stock’s reaction has been dramatic but increasingly measured. Over the past 30 trading days, shares have climbed 75.14?% (based on the most recent intraday price of €6.20, which was down 1.59?% on the session) and 77.97?% (based on the prior Friday’s close of €6.30). That rally still leaves the stock 19.75?% below its 52?week high of €7.85. The 14?day relative strength index sits at 73.9, indicating an overbought condition that, combined with the fixed offer price, suggests limited near-term upside.
Analysts have accordingly recalibrated their views. H.C.?Wainwright downgraded the stock from Buy to Neutral with a $7.50 target, while Berenberg moved to Hold at $7.45. TD?Cowen and Cantor Fitzgerald also issued Hold and Neutral ratings, respectively. The rationale is uniform: with a firm cash component and only milestone-linked upside, the stock now trades on deal completion risk rather than clinical potential. Yet Cathie?Wood of Ark Invest called the transaction a “well-deserved” return for shareholders; her fund sold 1.12?million shares but still holds 3.19?million shares worth about $22.78?million.
The broader regulatory environment has also shifted. An April 2026 executive order from President Trump directed the FDA to accelerate reviews of psychedelic therapies, and the agency followed up in July with specific clinical trial guidance. Industry estimates peg the global psychedelic drug market at $4.08?billion in 2025, expanding to $8.75?billion by 2031. For context, Johnson & Johnson’s approved nasal spray Spravato — a ketamine-derived treatment — generated $584?million in second?quarter 2026 sales, up 40?% year?over?year.
Atai Beckley at a turning point? This analysis reveals what investors need to know now.
Lilly’s shopping spree continues: earlier in 2026 it agreed to buy Centessa for $7.8?billion and Kelonia for $7?billion. The Atai Beckley deal, however, marks its first foray into psychedelics. Evercore analysts described the landscape as a “rising-tides scenario” that could encourage more large-cap entrants, despite the FDA’s 2024 rejection of Lykos’ MDMA application. For Atai Beckley shareholders, the Lilly offer transforms a long?shot clinical wager into a concrete, time?bound payout — provided the milestones are met and the deal closes as planned.
Ad
Atai Beckley Stock: New Analysis - 20 July
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
